News-Medical.Net on MSN

Evidence grows for pirtobrutinib as a safer and effective alternative for CLL and SLL

Pirtobrutinib, a non-covalent Bruton tyrosine kinase (BTK) inhibitor, met the primary endpoint for non-inferiority in terms ...